Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

SRI prostate cancer drug gets support from NCI
July 2007
SHARING OPTIONS:

MENLO PARK, Calif.SRI International, an independent nonprofit research and development organization, recently received support through the Rapid Access to Intervention Development (RAID) program of the National Cancer Institute (NCI), with those resources to be used to further the preclinical development of SRI's drug SR16388 to treat advanced cancers. This novel antiangiogenic drug is currently in development for the treatment of multiple tumor types, including metastatic prostate cancer.    "SR16388 is the third SRI drug candidate to be awarded  development support from the National Cancer Institute," says Dr. Nathan Collins, executive director of drug discovery in SRI's Biosciences Division. "This latest award demonstrates the broad capabilities of SRI as a premier research and development organization with a strong drug pipeline." 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.